Branding & Marketing

MMIT Reality Check on Chemotherapy-Induced Nausea and Vomiting (June 2021)

June 11, 2021

According to our recent payer coverage analysis for chemotherapy-induced nausea and vomiting (CINV) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for chemotherapy-induced nausea and vomiting (CINV) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for CINV treatments shows that under the pharmacy benefit, about 25% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: New entrants to this market have benefited from rapid uptake, driven both by clinical advantages and by favorable reimbursement dynamics. Merck & Co., Inc.’s Emend (aprepitant) and Aloxi (palonosetron hydrochloride) have the most favorable coverage compared with other brand name antiemetics.

by Matt Breese

MMIT Reality Check on Hereditary Angioedema (June 2021)

June 4, 2021

According to our recent payer coverage analysis for hereditary angioedema (HAE) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for hereditary angioedema (HAE) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for HAE treatments shows that under the pharmacy benefit, about 57% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: Health plans don’t differentiate coverage among provider-administered products, and access to HAE products is not limited at the brand level. However, increased competition is expected as more prophylactic therapies enter the market.

by Matt Breese

MMIT Reality Check on Non-Small Cell Lung Cancer BRAF+ (May 2021)

May 28, 2021

According to our recent payer coverage analysis for non-small cell lung cancer BRAF+ treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for non-small cell lung cancer BRAF+ treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for non-small cell lung cancer BRAF+ treatments shows that under the pharmacy benefit, about 71% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: Coverage is under the pharmacy benefit. Prior authorization is required for both Mekinist and Tafinlar to ensure appropriate use. Payer policies for lung cancer typically follow National Comprehensive Cancer Network (NCCN) guidelines.

by Matt Breese

MMIT Reality Check on Cervical Cancer (May 2021)

May 21, 2021

According to our recent payer coverage analysis for cervical cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for cervical cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for cervical cancer treatments shows that under the pharmacy benefit, about 37% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In September 2020, the FDA expanded the use of Roche’s CINtec PLUS Cytology test to help clinicians determine which women who test positive for human papillomavirus (HPV) via cobas 6800/8800 Systems require further diagnostic procedures to prevent disease progression.

by Matt Breese

MMIT Reality Check on Atopic Dermatitis (May 2021)

May 14, 2021

According to our recent payer coverage analysis for atopic dermatitis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for atopic dermatitis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for atopic dermatitis treatments shows that under the pharmacy benefit, about 23% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: Sanofi and Regeneron’s Dupixent (dupilumab) and Pfizer Inc.’s Eucrisa (crisaborole) are competing for preferred status after topical corticosteroids and topical calcineurin inhibitors and phototherapy. Numerous companies are poised to enter the same market space, many with new biological agents.

by Matt Breese

MMIT Reality Check on Narcolepsy (May 2021)

May 7, 2021

According to our recent payer coverage analysis for narcolepsy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for narcolepsy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for narcolepsy treatments shows that under the pharmacy benefit, about 54% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In October 2020, the FDA gave another approval to Harmony Biosciences Holdings, Inc.’s Wakix (pitolisant) for the treatment of cataplexy in adults with narcolepsy. The agency initially approved the selective histamine 3 (H3) receptor antagonist/inverse agonist on Aug. 15, 2019.

by Matt Breese